Latest Intelligence on Pharmaceuticals and Healthcare in Europe

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential

New pooled data confirm Vimpat's efficacy in the adjunctive treatment of uncontrolled partial-onset seizures in adults. The drug represents a new treatment option for patients with uncontrolled epilepsy, but its inferior efficacy to Keppra is expected to limit its uptake. Nevertheless, future indication expansions in migraine and fibromyalgia may expand Vimpat's commercial potential.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

UCB: Vimpat offers hope to sufferers of uncontrolled epilepsy

UCB has announced that the European Commission has approved Vimpat for the treatment of epilepsy in patients 16 years and older. Vimpat holds the potential to improve quality of life for patients across the seven major markets whose seizures remain inadequately controlled with available treatments, and will also help to support UCB's market leading epilepsy franchise.

Published By Datamonitor
03 Sep 2008
CommentWire
CommentWire

UCB: positive outlook for Keppra

UCB has reported significant top-line phase III results for its epilepsy medicine Keppra over placebo in reducing the frequency of partial onset seizures in pediatric patients. While these results demonstrate Keppra's broad potential to reduce the burden of epilepsy across a wider-range of patients, they also point to a positive future for UCB's epilepsy franchise.

Published By Datamonitor
20 Apr 2007
CommentWire
CommentWire

UCB: IV Keppra gets EU regulatory nod

In addition to receiving European approval for IV Keppra, the EMEA has also recommended the drug for use in juvenile myoclonic epilepsy. Unlike other leading anti-epileptics makers, UCB's strategy for Keppra has been to focus exclusively on penetrating the epilepsy market. The additional formulation and potential new indication are testimony to this, and should further promote brand loyalty.

Published By Datamonitor
27 Apr 2006
CommentWire
CommentWire

UCB: innovative payment scheme behind Cimzia approval sets precedent in rheumatology

UCB's new rheumatoid arthritis drug, Cimzia, has been recommended for use on the NHS but only in conjunction with a company-sponsored patient access scheme. As such, UCB will cover all treatment costs for the first 12 weeks of therapy. This is a shrewd way of ensuring Cimzia's use by the cost-conscious NHS, and could herald change in both prescribing practices and future NICE submissions.

Published By Datamonitor
26 Jan 2010
CommentWire
CommentWire

UCB: European submission for rheumatoid arthritis treatment

UCB's certolizumab is marketed under the brand name Cimzia. The submission for rheumatoid arthritis treatment, if accepted, will make it the first and only PEGylated, Fc-Free anti-TNF (tumor necrosis factor) alpha biologic therapy in Europe. Certolizumab has some advantages over current treatments but its late arrival on the market will work against it as it tries to claim market share.

Published By Datamonitor
07 Jul 2008
CommentWire
CommentWire

UCB: development of Keppra's successor makes headway

UCB has initiated a Phase III clinical program for brivaracetam as an adjunctive treatment in partial-onset epilepsy. Should it perform well here and gain marketing approval, the launch of this drug would serve to strengthen UCB's epilepsy franchise, as well as potentially representing an important treatment option for patients with refractory epilepsy.

Published By Datamonitor
26 Oct 2007
CommentWire
CommentWire

UCB: continuing the European Mid-Pharma consolidation craze

Having enjoyed past success from acquisitions, Belgian-based UCB is now looking to Schwarz Pharma, with its impressive late-stage pipeline, to boost its growth potential. This merger agreement is the latest in a recent 'acquisition frenzy', and highlights the current trend towards consolidation in the European pharmaceutical sector.

Published By Datamonitor
26 Sep 2006
CommentWire
CommentWire

UCB: Cimzia making good progress

A phase II clinical trial involving Cimzia, UCB and Nektar's anti-TNF alpha antibody, has demonstrated it to be effective and safe in treating psoriasis. However, despite this latest positive news, and Cimzia's advantages over other biologics, the drug candidate's anticipated late entry to the psoriasis drug market will have a negative impact upon its chances of success.

Published By Datamonitor
20 Jul 2006
CommentWire
CommentWire

UCB/Schwarz: a leading CNS proposition moves a step closer

The $5.5 billion takeover of Schwarz Pharma by Belgian rival UCB looks likely to go ahead, as preliminary figures show that UCB has received tenders in excess of 76% of the share capital of Schwarz Pharma. In addition to generating significant synergies, the deal is expected to create a leading neurology-focused pharmaceuticals group.

Published By Datamonitor
12 Dec 2006

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.